^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG CLASS:

Apoptosis inhibitor

7d
San-Huang-Chai-Zhu formula alleviates intrahepatic cholestasis through PPARα-mediated bile acid homeostasis and MKK4/JNK pathway. (PubMed, Cytotechnology)
The therapeutic potential of SHCZF was evaluated in alpha-naphthylisothiocyanate (ANIT)-induced IC rat model, with ursodeoxycholic acid (UDCA) used as positive control...Importantly, GW6471 altered the regulatory effects of SHCZF on MKK4/JNK pathway and bile acid homeostasis. SHCZF improves IC by regulating PPARα-mediated bile acid homeostasis and MKK4/JNK pathway.
Journal
|
MAP2K4 (Mitogen-Activated Protein Kinase Kinase 4) • PPARA (Peroxisome Proliferator Activated Receptor Alpha)
10d
Potentiating BSEP-mediated bile acid efflux reverses first-line tyrosine kinase inhibitor resistance in hepatocellular carcinoma. (PubMed, Cancer Lett)
Mechanistic assays revealed that ursodeoxycholic acid (UDCA) upregulated BSEP and reversed resistance via an FXR-independent mechanism: UDCA directly binds cortactin (CTTN), reduces its PRMT1-dependent mono-methylation, and promotes CTTN degradation via chaperone-mediated autophagy, thereby enabling YY1 nuclear translocation and transcriptional activation of BSEP. Clinical specimen analyses corroborated an inverse BSEP-CTTN relationship and UDCA modulation. These findings identify impaired BSEP-mediated BA efflux and GCA accumulation as metabolic features of TKI resistance and support targeting the CTTN/YY1/BSEP axis, including UDCA, to overcome resistance.
Journal
|
ABCB1 (ATP Binding Cassette Subfamily B Member 1) • PRMT1 (Protein Arginine Methyltransferase 1) • CTTN (Cortactin) • YY1 (YY1 Transcription Factor)
14d
Ursodeoxycholic Acid Alleviates DSS/AOM-Induced Colorectal Cancer in Mice by Inhibiting PI3K/Akt/mTOR Signaling Pathway. (PubMed, Drug Des Devel Ther)
These findings suggest that UDCA exerts its anti-tumor effects primarily through direct inhibition of the EGFR-mediated PI3K/Akt/mTOR pathway, accompanied by partial restoration of the intestinal immune-metabolic microenvironment. This study provides new mechanistic insights supporting the therapeutic application of UDCA in CRC.
Preclinical • Journal
|
EGFR (Epidermal growth factor receptor)
20d
Efficacy & Safety of Oral Adjuvants to Phototherapy in Neonatal Hyperbilirubinemia (clinicaltrials.gov)
P4, N=80, Recruiting, Amira Adel Fouly | Not yet recruiting --> Recruiting | Trial completion date: Dec 2024 --> Jun 2026 | Trial primary completion date: Oct 2024 --> Jun 2026
Enrollment open • Trial completion date • Trial primary completion date
28d
TUDCA as a Therapy for Ulcerative Colitis (UC) (clinicaltrials.gov)
P1, N=14, Completed, Washington University School of Medicine | Recruiting --> Completed
Trial completion
28d
Prospective study of patients with immune checkpoint inhibitor-induced hepatitis; characterization of liver injury, outcome of therapy, and management of steroid-unresponsive and steroid-dependent hepatitis. (PubMed, J Immunother Cancer)
Nearly half of patients developing ir-hepatitis had an inadequate response to steroids and needed MMF as a secondary immunosuppressant. Patients with mixed DILI were more likely to respond to steroids, while alcohol consumption was associated with inadequate steroid response. Immune analyses showed high T cell infiltration in the liver among patients with ir-hepatitis.
Journal • Checkpoint inhibition
|
CD20 (Membrane Spanning 4-Domains A1) • CD8 (cluster of differentiation 8) • NCAM1 (Neural cell adhesion molecule 1) • FOXP3 (Forkhead Box P3)
1m
Somatostatin Effect on Growth Factors in Hepatocellular Carcinoma. (PubMed, Curr Issues Mol Biol)
Eighteen patients with advanced Primary Biliary Cholangitis (stage III and IV) before and after Ursodeoxycholic acid (UDCA) treatment were also studied...It was not significantly increased in HCC, but it was reduced by octreotide and was increased after UDCA. In this retrospective observational study, somatostatin and its analog octreotide have a significant effect on several growth factors involved in HCC pathogenesis.
Journal
|
IGF1 (Insulin-like growth factor 1) • GAST (Gastrin 2)
1m
Quercetin in Patients With XIAP (X-linked Inhibitor of Apoptosis) Deficiency (clinicaltrials.gov)
P1, N=12, Recruiting, Children's Hospital Medical Center, Cincinnati
New P1 trial
|
IL18 (Interleukin 18) • XIAP (X-Linked Inhibitor Of Apoptosis)
2ms
New P2/3 trial
2ms
Synergistic Neuroprotective Effects of Taurine and Tauroursodeoxycholic Acid on the Neurovascular Unit in Hypoxia-Reoxygenation Injury. (PubMed, Rejuvenation Res)
Furthermore, they acted together on the p38 mitogen-activated protein kinase (MAPK) signaling pathway, and the addition of the p38 inhibitor SB203580 partially inhibited the expression of p38MAPK. Thus, the combined action of these drugs protected the NVU.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • MMP2 (Matrix metallopeptidase 2) • BAX (BCL2-associated X protein) • CASP3 (Caspase 3) • MMP9 (Matrix metallopeptidase 9) • IL1B (Interleukin 1, beta) • TJP1 (Tight Junction Protein 1) • CLDN5 (Claudin 5)